Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia

T-cell prolymphocytic leukemia (T-PLL) is a rare, mature T-cell neoplasm with a heterogeneous clinical course. With the advent of novel treatment options that will potentially change the management of patients with T-PLL, it has become necessary to produce consensus guidelines for the design and conduct of clinical trials. The T-PLL International Study group (TPLL-ISG) set out to define standardized criteria for diagnosis, treatment indication, and evaluation of response. These criteria will facilitate comparison of results from clinical trials in T-PLL, and will thus support clinical decision making, as well as the approval of new therapeutics by healthcare authorities.

Source: Blood - October 2, 2019 Category: Hematology Authors: Staber, P. B., Herling, M., Bellido, M., Jacobsen, E. D., Davids, M. S., Kadia, T. M., Shustov, A., Tournilhac, O., Bachy, E., Zaja, F., Porkka, K., Hoermann, G., Simonitsch-Klupp, I., Haferlach, C., Kubicek, S., Mayerhoefer, M. E., Hopfinger, G., Jaeger, Tags: Special Reports, Free Research Articles, Lymphoid Neoplasia Source Type: research